TY - JOUR AU - Robert-Gangneux, Florence AU - Meroni, Valeria AU - Dupont, Damien AU - Botterel, Françoise AU - Garcia, José Aguado AU - Brenier-Pinchart, Marie-Pierre AU - Accoceberry, Isabelle AU - Akan, Hamdi AU - Abbate, Isabella AU - Boggian, Katia AU - Bruschi, Fabrizio AU - Carratalà, Jordi AU - David, Miruna AU - Drgona, Lubos AU - Djurković-Djaković, Olgica AU - Farinas, Maria Carmen AU - Genco, Francesca AU - Gkrania-Klotsas, Effrossyni AU - Groll, Andreas AU - Guy, Edward AU - Hirzel, Cédric AU - Khanna, Nina AU - Kurt, Özgür AU - Junie, Lia Monica AU - Lazzarotto, Tiziana AU - Len, Oscar AU - Mueller, Nicolas AU - Munoz, Patricia AU - Pana, Zoi Dorothea AU - Roilides, Emmanuel AU - Stajner, Tijana AU - van Delden, Christian AU - Villena, Isabelle AU - Pelloux, Hervé AU - Manuel, Oriol T1 - Toxoplasmosis in Transplant Recipients, Europe, 2010–2014 T2 - Emerging Infectious Disease journal PY - 2018 VL - 24 IS - 8 SP - 1497 SN - 1080-6059 AB - Transplantation activity is increasing, leading to a growing number of patients at risk for toxoplasmosis. We reviewed toxoplasmosis prevention practices, prevalence, and outcomes for hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT; heart, kidney, or liver) patients in Europe. We collected electronic data on the transplant population and prevention guidelines/regulations and clinical data on toxoplasmosis cases diagnosed during 2010–2014. Serologic pretransplant screening of allo-hematopoietic stem cell donors was performed in 80% of countries, screening of organ donors in 100%. SOT recipients were systematically screened in 6 countries. Targeted anti-Toxoplasma chemoprophylaxis was heterogeneous. A total of 87 toxoplasmosis cases were recorded (58 allo-HSCTs, 29 SOTs). The 6-month survival rate was lower among Toxoplasma-seropositive recipients and among allo-hematopoietic stem cell and liver recipients. Chemoprophylaxis improved outcomes for SOT recipients. Toxoplasmosis remains associated with high mortality rates among transplant recipients. Guidelines are urgently needed to standardize prophylactic regimens and optimize patient management. KW - toxoplasma infection KW - transplantation KW - transplant recipient KW - cerebral toxoplasmosis KW - hematopoietic stem cell transplant KW - chemoprophylaxis KW - cotrimoxazole KW - parasites KW - Europe KW - Toxoplasma DO - 10.3201/eid2408.180045 UR - https://wwwnc.cdc.gov/eid/article/24/8/18-0045_article ER - End of Reference